This is the first in a series of papers that will present systematic reviews of the prevalence and incidence of psychiatric disorders drawn from studies published in the years 1980 to 2000. The series will discuss the implications of these epidemiological findings for mental health policy and practice.
F
uller Torrey concluded his review of over 70 prevalence studies of schizophrenia with a compelling statement: "As tragic a disease as schizophrenia is, it is also one of the greatest intellectual challenges of contemporary medicine" (1, p 606). In the same review, Torrey identified a series of beguiling questions that remained unanswered: How substantial are geographical differences in the prevalence of schizophrenic disorders? Do pockets of high or low prevalence exist? Have there been robust changes in the incidence of schizophrenic disorders over time? In the current systematic review of studies published between the years 1980 and 2000, we revisit such questions and relate them to mental health policy and practice.
Prevalence vs Incidence
"Prevalence" quantifies the proportion of individuals in a population who have a disease during a specific time period. "Incidence" refers to the number of new cases of disease that develop in a population of individuals at risk during a specific time period. While both prevalence and incidence rates have similar denominators (that is, the population at risk) and include new cases in their numerator, prevalence rates also contain existing cases in the numerator. Thus, although incidence rates can approach prevalence rates in diseases with short duration, this is not the case with schizophrenia. For example, the US Epidemiological Catchment Area (ECA) study found the incidence rate for schizophrenia to be only 27% of the prevalence rate (2) . Incidence and prevalence data also have different uses. Because prevalence data provide a snapshot of the burden of disease on society at a specific time, they can be used to inform planning efforts and to estimate ideal resource allocations. Incidence is more useful in examining changes in the disease risk in different populations over time. Moreover, because incidence studies do not mix old and new cases, they are better able to examine causal relations. For example, they can help determine whether potential risk factors, such as birth complications, lead to the subsequent development of schizophrenia. An understanding of causal relations can lead to the development of effective prevention and early intervention efforts. Readers interested in further examination of the methods and applications of incidence and prevalence research are referred to Hennekens and others (3) .
Why A Systematic Review?
Previous reviews looked at older studies with widely varying methodologies and found 6-to 14-fold variation in incidence and prevalence rates of schizophrenia (1, 4) . However, individual studies that use identical methodologies across study sites, such as the International Study of Schizophrenia (ISoS) (5) , have found only 2-to 3-fold variation worldwide. To help decrease the likelihood that variation of rates is an artifact of methodology, we used an a priori protocol that minimizes missing relevant studies, maximizes comparability across studies, and restricts inclusion of studies to those using highquality methods. If this systematic process reduces the variation in studies observed in previous reviews and leads to findings closer to the range of the ISoS, we can be more confident about the conclusions drawn from our analyses.
Methods

Search Strategy to Identify Relevant Articles
We searched the Medline and HealthSTAR electronic databases for relevant epidemiological studies, using a search strategy with high sensitivity. The key indexing terms epidemiology, prevalence, and incidence were combined with the search terms mental disorders, schizophrenic disorders, and schizophrenia. We limited the search to human subjects and to English-language studies published between January 1, 1980, and December 31, 2000. (Publications in languages other than English were excluded because we lacked resources for both translation and appraisal of study characteristics.) We also searched the reference lists of all identified relevant primary and review articles.
Study Selection
The following screening criteria were used to select studies:
1. Study design. Studies were to be either community surveys of the general population using probability sampling techniques or those that surveyed the entire population of a defined area. We also included studies using key informant methodology, which involves establishing a list of services and agencies in a defined area that are likely sites of contact for potential cases, if it was evident that the case-finding covered an extensive network of mental and nonmental health services. Because the key-informant method aims to ascertain all cases within a specified area, studies that identified cases from treatment settings only were excluded. After we completed the screening stage of the review, we modified these criteria for incidence studies, because only a single study could be included. Incidence studies were eligible for inclusion if they used case-register methods that surveyed, at minimum, primary care general medical services.
2. Study population. We included prevalence studies that covered the entire age range of the general population, as well as studies that focused only on adults (for example, aged 18 to 65 years). However, we included only those incidence studies that examined subjects aged 15 years and over. We did not include studies meeting our eligibility criteria but falling outside these age ranges, because it did not seem feasible for our present review, especially given the relative lack of studies examining other age groups (such as children and the elderly).
4. Diagnostic criteria. We selected only studies using operationalized diagnostic criteria and case identification based on either standardized instruments or clinician diagnosis. Where studies used ICD or DSM classification systems, we included only those using ICD-9 or DSM-III and later criteria. We excluded studies published prior to 1980, because we judged that they would be unlikely to meet the above criteria. We also excluded studies if the case definition was not explicit. We scrutinized studies incorporating medical records for inclusion of corroborating diagnostic methods, and we excluded studies relying solely on medical records.
We initially applied the above eligibility criteria to the citations and abstracts generated by the search. Based on this information, we excluded publications definitely not meeting the inclusion criteria. When an article met the inclusion criteria, or when there was not enough information to definitely exclude it, we retrieved the full text. We then reviewed these potentially relevant articles to determine whether the inclusion criteria were in fact met. We excluded studies not meeting the eligibility criteria at this stage and documented the reasons for exclusion. Studies selected for inclusion in the review were formally abstracted, as described below.
Data Extraction
We designed a data collection form to extract several key components from relevant primary articles. These items included bibliographic information on the article; specific study design characteristics, such as the study population and the methods used to obtain the study sample; case-finding techniques; and diagnostic criteria used. We extracted prevalence and incidence data including overall, sex-specific, and agespecific rates from each article, and when relevant, we noted the prevalence period assessed in the study (for example, point, 1-year, or lifetime). Where serial publications were based on the same data, only the most recent and definitive results were extracted and included in the analysis.
Data Analysis Qualitative Analysis
We performed a qualitative analysis of the studies' data to summarize the rates. We assessed the following variables to elucidate any observed differences among rates:
1. Study population. This includes the country or region studied, the year(s) in which assessment of prevalence or incidence was carried out, the age range studied (the entire general population or adults only), the type of community studied (city, town, or rural area), and the type of population covered (the broad population or a specific ethnic group).
2. Sample characteristics. These include the sampling approach (probability sample based on census lists, electoral roll, or household survey), the sample size, the response rate, and the types of residence included (for example, households, nursing homes, or hospitals).
3. Case ascertainment and diagnosis. This includes the diagnostic instrument used, the qualifications of the person administering the instrument (for example, lay interviewer or clinician) the information source used to ascertain cases (interview with subject, informant, or physician, or medical records) the means by which diagnosis was established (for example, by clinician or by computer algorithm), the diagnostic criteria used, and the case definition used (broad or narrow).
Estimation of Pooled Best-Estimate Rates
Each set of rates was pooled based on a Bayesian approach to metaanalysis, using the Fastpro software program (version 1.7) by Eddy and Hasselblad. Readers interested in a more detailed discussion of this approach should refer to Eddy and others (6) . We calculated the pooled or best-estimate of effect values (called "median of the posterior" in this method) using Jeffrey's prior and a hierarchical model. We used a randomeffects model in the expectation that there would be significant heterogeneity of rates among studies included in the pooled rate.
Heterogeneity Analysis of Pooled Rates
Because we expected significant heterogeneity of rates within the studies pooled, we defined a systematic method for exploring why studies reported varying rates. Each of the pooled rates was analyzed for heterogeneity using chi-square tests according to Fleiss' method (7). This involves grouping the proportions according to the methodological variables that may be contributing to differences among them. We initiated the procedure by listing the proportions in descending order, dividing them into 2 groups by the median value, and categorizing them according to each of the variables that were defined a priori as being of interest (for example, country studied). Rates from individual studies were then pooled according to variables that had the highest magnitude of differences among groups. Figure 1 outlines the procedure used to examine heterogeneity within the best-estimate pooled rates.
Results
Description of Studies
From the citations and abstracts generated by the initial electronic search, we identified 26 prevalence studies and 8 incidence studies that potentially met inclusion criteria; additionally, we identified 6 review papers. We retrieved the full texts of these articles. To complete the initial stage of study identification, we searched all reference lists of identified studies and reviews, generating an additional 13 potential prevalence studies and 45 potential incidence studies, for which we also obtained the full texts.
Of the 39 prevalence papers for which full-text articles were reviewed, we excluded a total of 15 articles; 13 studies did not meet eligibility criteria, and 2 presented duplicate data. Thus, we obtained data from 24 papers that met our eligibility criteria (2, . These reported the results of 18 unique primary investigations of prevalence of schizophrenia and related disorders. Table 1 documents our reasons for excluding those prevalence studies fulfilling all but 1 inclusion criterion (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) . Of the 53 papers reporting incidence, 44 were excluded; 40 studies did not meet eligibility criteria, and 4 reported duplicate data. Thus, we could include data from 9 publications reporting incidence of schizophrenia (2, 5, (43) (44) (45) (46) (47) (48) (49) , describing 8 distinct primary investigations of incidence. Seven of the excluded studies almost met inclusion criteria; Table 1 presents reasons for their exclusion (41, (50) (51) (52) (53) (54) (55) .
Prevalence Studies
We present findings for the 16 prevalence papers reporting 1-year or lifetime prevalence rates only (Tables 2 and 4) , because relatively few studies reported data for point prevalence (2, 10, 12, 17, 20, 24, 27, 29) or 6-month prevalence (13, 17, 20, 24, 30) . We present findings separately for schizophrenic disorders, schizophrenia, and schizophreniform disorder because these were the diagnostic categories for which prevalence rates were most commonly reported, and also because we wish to maintain important distinctions between disorders that are occasionally conflated. We analyzed data only when 3 or more rates were reported, because this was the minimum number of values required to produce pooled rates.
All but 1 of the studies shown in Table 2 are community surveys that examine a series of mental disorders, using samples ranging from approximately 500 (16) to 20 000 (18) in size. One study involves a complete survey of key informants based on an at-risk population of about 65 000 (9) . For each of these studies, the percentage confidence interval (CI) width or error rate for estimated prevalence at a 95%CI may be calculated using the formula provided by Kelsey and colleagues (56, p 282 (20) , and in rural villages in Taiwan (22) to 0.9 per 100 in the US ECA study (18) , a more than 4-fold difference. If the ECA study is excluded as an outlier, the 1-year prevalence rates vary up to 0.42 per 100, a 2.1-fold difference. The highest rates, observed in the US ECA study, followed by the Swedish study (9) , may be partly explained by the inclusion of institutionalized cases. One-year prevalence rates for schizophreniform disorder ranged from 0 per 100 in New Zealand (20) and Edmonton (24) to 0.1 per 100 in the US ECA study (18) .
Lifetime Prevalence. For schizophrenic disorders, lifetime prevalence rates ranged from 0.4 per 100 in New Zealand (21) to 2.2 per 100 in Finland (19) and in the US National Comorbidity Study (NCS) (11), a 5.5-fold difference. The lifetime prevalence rates for schizophrenia varied considerably, ranging from 0.12 per 100 in Hong Kong (15) to 1.6 per 100 in Puerto Rico (26), a difference of over 13-fold. The Puerto Rico, US ECA, and Finland studies included institutionalized cases, which may in part explain the higher rates from these studies. It is notable that low lifetime prevalence rates were reported in all reviewed studies conducted in Asian countries (Hong Kong, Taiwan, and Korea). The lifetime prevalence rates for schizophreniform disorder ranged from 0 per 100 in Taiwan (22) to 0.2 per 100 in both the US ECA (18) and Puerto Rico (26) studies. If the outlying rates reported in Taiwan are excluded, all studies reported rates in the range of 0.06 to 0.2 per 100, a 3-fold variation. Figure 1 Steps for examining heterogeneity in best-estimate pooled rates have very similar rates across most studies. Although the studies conducted in Taiwan and Korea both show lower lifetime prevalence rates for female subjects, compared with male subjects, differences are not reported to be significant.
Sex-Specific Lifetime Prevalence.
Estimation and Heterogeneity Analysis of Pooled BestEstimate Rates
Schizophrenic Disorders. The best-estimate rates for 1-year and lifetime prevalence are 0.60 per 100 and 1.45 per 100, respectively (Table 2) . Heterogeneity analysis revealed significant differences across each set of proportions. For both 1-year and lifetime prevalence, the variable found to have the greatest magnitude of difference across proportions was type(s) of residence sampled, although this variable likely does not explain much of the heterogeneity in rates ( Table 5 ).
The pooled 1-year rate for studies that sampled both households and institutions was approximately twice that for studies assessing household populations only (0.85 vs 0.43 per 100, respectively).
Schizophrenia. The best-estimate rates for 1-year and lifetime prevalence are 0.34 per 100 and 0.55 per 100, respectively (Table 2 ). Heterogeneity was found across both 1-year and lifetime rates. As shown in Table 5 , the pooled 1-year and lifetime rates for studies that sampled both households and institutions there was approximately 3 times those of the studies including only household samples. The pooled lifetime rate for Asian studies (0.25 per 100) was almost 4 times lower than that of non-Asian studies (0.88 per 100).
Schizophreniform Disorder. The best-estimate rate for 1-year and lifetime prevalence was found to be 0.09 per 100 and 0.11 per 100, respectively (Table 2 ). Heterogeneity analysis demonstrated significant differences across lifetime prevalence rates only. As shown in Table 5 , the pooled rate for studies conducted in Asia was found to be 6 times lower than that of studies carried out in other parts of the world (0.03 vs 0.18 per 100, respectively). Table 3 presents the findings for the 8 studies for which 1-year incidence rates of schizophrenia could be extracted. Studies reporting rates for schizophrenia spectrum disorders (2) were not included, because this broader category was not commonly reported.
Incidence Studies
Most studies shown in Table 3 are key-informant surveys, with at-risk populations ranging from approximately 73 000 (43) to 5 000 000 (5). The only study that involved a community-based sampling design was the US ECA study (49) , with a sample size of approximately 20 000. For the most part, the reviewed studies used the Present State Examination (PSE) and an algorithm such as the CATEGO system to extract diagnoses (57) . Only the ECA study used lay interviewers; all other studies used clinicians. Qualitative Analysis The 1-year incidence for schizophrenia ranged from 3.6 per 100 000 in Vancouver (46) to 200 per 100 000 in the US ECA study (49) . While the study reporting the lowest estimate used a case-ascertainment method, the ECA study is the lone investigation cited here that was based on a community sample. If the ECA is excluded as an outlier, the rates vary up to 22.6 per 100 000, a 6.3-fold variation. Restricting our analyses to only those that examined ICD rates, we found that rates varied from 4.8 to 22.6 per 100 000, a 4.7-fold variation. The 1-year incidence rates between sexes were less comparable than for prevalence studies: 2 of the 3 studies reported male rates about twice that of female rates. 
Estimation and Heterogeneity Analysis of Pooled Best-Estimate Rates
We excluded the ECA study from quantitative analysis because its extreme outlier rate and large size would outweigh all other results. Although there were 2 studies that reported rates for both an ICD and DSM diagnosis, we included only the ICD rates for these studies in the analysis, because this was consistent with most of the remaining studies. The bestestimate incidence rate was 11.1 per 100 000 (Table 3) . Heterogeneity analysis revealed significant differences across 1-year incidence rates. The only variable for which heterogeneity was demonstrated was type of sampling: studies that used key-informant methodology had a lower pooled rate (10.5 per 100 000), compared with studies that used case registers to ascertain cases (12.7 per 100 000) ( Table 5 ). This variable likely does not explain much of the heterogeneity in rates, however, as shown by the overlapping CIs of the 2 pooled rates.
Discussion
Consistent with previous review findings (1,4), we found variability in the prevalence and incidence rates of schizophrenia.
However, the magnitude of variation found in our review is considerably less. Five of the 7 sets of rates presented had a variation that was no more than 2-to 5-fold, a rate much closer to the 2-to 3-fold variation reported in the ISoS (5), the only global study of schizophrenia with standardized methodology across sites. Lifetime prevalence continues to vary 13-fold, but this is likely attributable to recall bias (23) . Given that our review systematically excluded studies of low quality with poorly standardized methods, it is likely that much of the 6-to 14-fold variation found in other reviews reflects methodological artifact.
If modest variation in schizophrenia persists, the next question is: Why? Our review is able to bring some data to bear on this question, albeit at the population, rather than individual, level. One variable that may contribute significantly to the variability across prevalence studies is location in an Asian vs non-Asian country (Figure 2 ). However, whether these differing rates are to due methodological, genetic, environmental, or subtler sociological variables, such as stigma and underreporting, remains to be determined. Low rates are also not exclusive to Asian nations: New Zealand (20) and the Netherlands (8) were also found to have low prevalence of schizophrenia.
Another potential explanation for variation in rates is trends over time (Figure 3) . Estimates of the 1-year incidence of schizophrenia were greater in the more recent studies, between the years 1979 and 1993. This finding may be interpreted as conflicting with other reports indicating that the incidence of schizophrenia may possibly be in decline (58) . However, owing to the cross-national basis of these temporal trends, an alternative explanation may be that demographic or case-ascertainment differences between study sites confound the apparently increasing rates.
It should be noted that the ECA study had a 1-year incidence rate that was 18 times the pooled rate from other studies (Table 3). Because the ECA represents the only true communityincidence study, its results warrant consideration when contrasted with the lower incidence of case ascertainment and key-informant and register-incidence studies. However, since the ECA study reported that 64% of the 1-year prevalence cases had contact with the health system (2), it is likely that the above-noted discrepancy was not solely due to lower case There were intriguing sex distributions among studies included in this review. Nine of the 10 prevalence studies that include sex-specific data report very similar rates. Two of the 3 incidence studies report rates in male subjects that are twice those found in female subjects (Table 4 ). Since prevalence is directly proportional to incidence multiplied by duration (59), an explanation for higher male incidence rates with equal prevalence rates could be that the duration of illness in male subjects is shorter. Alternatively, male subjects may have higher mortality rates or the incidence rates may be higher in female subjects outside the 15 years and older age range. These findings warrant further investigation in a longitudinal study that uses a community sample and reports both prevalence and incidence rates over time.
The major implication of our findings for clinicians and policy makers is that pooled rates-even those presented in this study-may not accurately reflect the rates of local populations. An effort should be made to obtain local rates or, at minimum, to estimate local rates from a study with a population that most closely matches the local population. Health planners should also note that focusing only on incidence and prevalence rates of schizophrenia may underestimate its societal burden relative to other more prevalent disorders. Because schizophrenic disorders often begin when people are young, frequently produce longstanding or recurrent symptoms, and commonly result in the profound disablement of most affected individuals (60), they may exact a disproportionately large burden of suffering relative to their frequency in the population. Thus, despite their relatively low prevalence, it is important to continue attending to policies and practices that might better address the prevention, treatment, and support of people with schizophrenia and related disorders.
